A Single-center, Randomised, Double-blind, Adaptative, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food), and Pharmacodynamics or RO6806127 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2017
Price : $35 *
At a glance
- Drugs RG 7342 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; First in man
- Sponsors Roche
- 02 Nov 2017 Results published in the British Journal of Clinical Pharmacology
- 26 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Dec 2014 Planned End Date changed from 1 Nov 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.